Influences of brain tumor-associated pH changes and hypoxia on epileptogenesis

Acta Neurologica Scandinavica

Volumn 111, Issue 2, 2005, Pages 75-83

  Schaller, Bernhard ^a,b  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anti epileptic drug; Brain tumor; Pathophysiology; Seizure; Treatment

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOPOIETIN 1; ANGIOPOIETIN 2; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1; VASCULOTROPIN;

ACIDITY; ANAEROBIC FERMENTATION; ARTICLE; BLOOD PH; BRAIN HYPOXIA; BRAIN TUMOR; CHEMICAL ANALYSIS; DATA BASE; EPILEPTIC DISCHARGE; EPILEPTOGENESIS; GLYCOLYSIS; HISTOLOGY; HYPOXIC CELL; MAMMAL CELL; MEDICAL INFORMATICS; OUTCOMES RESEARCH; OXIDATIVE PHOSPHORYLATION; OXYGEN TENSION; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; SEIZURE; STRUCTURE ANALYSIS; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

BRAIN NEOPLASMS; EPILEPSY; HUMANS; HYDROGEN-ION CONCENTRATION; HYPOXIA, BRAIN; POSTOPERATIVE COMPLICATIONS;

EID: 12944281708     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2004.00355.x     Document Type: Article

References (88)

1. SCHALLER B. Usefulness of PET in diagnosis and treatment follow-up of brain tumors. A review. Neurobiol Dis 2004;15:437-48.
2. CASCINO GD. Epilepsy and brain tumors: implications for treatment. Epilepsia 1990;31(Suppl. 3):S37-44.
3. SCHALLER B, RÜEGG SJ. Brain tumor and seizures - pathophysiology and its implication for treatment revisited. Epilepsia 2003;44:1-10.
4. HAGLUND MM, OJEMANMN GA, HOCHMANN DW. Optical imaging of epiletiform and functional activity in human cerebral cortex. Nature 1992;338:668-72.
5. IRLBACHER K, BRANDT SA, MEYER BU. In vivo study indicating loss of intracortical inhibition in tumor associated epilpesy. Ann Neurol 2002;52:119-22.
6. FIDLER IJ, YANO S, ZHANG R et al. The seed and soil hypothesis: vascularization and brain metastasis. Lancet Oncol 2002;3:53-7.
7. CARMELIET P, FERRERA V, BREIER G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-39.
8. ZAGZAG D, NOMURA M, FRIEDLANDER DR et al. Geldanamyicn inhibits migration of glioma cells in vitro: a potential role for hypxoa-inducible factor (HIF-1 alpha) in glioma cell invasion. J Cell Physiol 2003;196:394-402.
9. BRINER P, PIRIBAUER M, FISCHER I et al. Vascular patterns in gliobasltoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 2003;13:133-43.
10. WIESNER HG, HÄNE A. Antiepileptic drug treatment before and after selective amygdalo-hippocampectomy. Epilepsy Res 2003;55:211-23.
11. KEMPSKI O, STAUB F, JANSEN M et al. Glial swelling during extracellular acidosis in vitro. Stroke 1988;19:385-92.
12. DEITMAR JW. Evidence for glial control of extracellular pH in the lack central nervous system. Glia 1992;5:43-7.
13. CHESLER M. The regulation and modulation of pH in the nervous system. Prog Neurobiol 1990;34:401-27.
14. KAIBARA T, TYSON RL, SUTHERLAND GR. Human cerebral neoplasms studied using MR spectroscopy: a review. Biochem Cell Biol 1998;76:477-86.
15. ZIEGLER A, VON KIELIN M, DECORPS M et al. High glycolytic activity in rat glioma demonstrated in vivo by correlation peak 1H magnetic resonance imaging. Cancer Res 2001;61:5595-600.
16. GILLIES RJ, SCHONACK PA, SECOMB TW et al. Causes and effects of heterogenous perfusion in tumors. Neoplasia 1999;1:197-207.
17. SEAGROVES TN, RYAN HE, LU H et al. Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol Cell Biol 2001;21:3436-44.
18. LEHERICY S, DUAU H, CORNU L et al. Correspondence between functional magnetic resonance imaging somatotopy and individual brain anatomy of the central region: comparison with intraoperative stimulation in patients with brain tumors. J Neurosurg 2000;92:589-98.
19. DUAU H, CAPELLE L, SICHEZ D et al. Intraoperative mapping of the subcortical language pathways using direct stimulation. An anatomo-functional study. Brain 2002;125:1-16.
20. DISBORW EA, SLUTSKY DA, ROBERTS TPL et al. Functional MRI at 1.5 tesla: a comparisons of the blood oxygenation level-dependent signal and electrophysiology. Proc Natl Acad Sci U S A 2000;97:9718-23.
21. OGAWA S, TANK DW, MENON R et al. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci U S A 1992;89:5951-55.
22. NARAZAN SM, ESFUHANI P, BLOOD AJ et al. Functional increases in cerebral blood volume over somatosensory cortex. J Cereb Blood Flow Metab 1995;15:754-65.
23. KWONG KK, BELLIVEAU JW, CHELSER DA et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci U S A 1992;89:5675-79.
24. FOX PT, RAICHLE ME: Focal physiological uncoupling of cerebral blood flow and oxidative metabolism during somatosensory stimulation in human subjects. Proc Natl Acad Sci U S A 1986;83:1140-44.
25. OGAWA S, MENON RS, TANK DW et al. Functional brain mapping by blood oxygenation bevel-do-pendent contrast magnetic resonance imaging. A comparison of signal characteristic with a biophyisological model. Biophys J 1993;64:2802-12.
26. SCHREIBER A, HUBBE U, ZIVEH S et al. The influence of gliomas and nongilal space-occupying lesions on blood-oxygen-level-dependent contrast enhancement. Am J Neuroradiol 2000;21:1055-63.
27. HOLODNY AI, SCHLUDER M, LIU WC et al. The effect of brain tumors on BOLD functional MR imaging activation in the adjacent motor cortex: implications for image-guided neurosurgery. Am J Neuroradiol 2000;21:1415-22.
28. SCHIBAUER H, FERRARI P, ROWLEY HA et al. Functional activity within the brain tumors: a magnetic source imaging study. Neurosurgery 2001;49:1313-20.
29. AUBERT A, COSTALAT R, DUAU H et al. Modeling of pathophysiological coupling between brain electrical activation, energy metabolism and hemodynamics: insights for the interpretation of intracerebral tumor imaging. Acta Biotheor 2002;50:281-95.
30. MAYHEW JEW. A measured look at neuronal oxygen consumption. Science 2003;299:1023-24.
31. THOMPSON JK, PETERSON MR, FREEMAN RD. Single-neuron activity and tissue oxygenation in the cerebral cortex. Science 2003;299:1070-72.
32. YUAN J, NARAYANAN L, ROCKWELL S et al. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res 2000;60:4372-6.
33. RUSSO CA, WEBER TK, VOLPE CM et al. An anoxia inducible endonuclease and enhanced DNA breakage as contributors to genomic instability in cancer. Cancer Res 1995;55:1122-8.
34. KONDO A, SAFEI R, MISHIMA M et al. Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res 2001;61:7603-7.
35. MORITA T, NAGAKI T, OKUMURA K et al. Evaluation of clastogenicity of formic acid, acetic acid, and lactic acid on cultured mammalian cells. Mutat Res 1990;240:195-202.
36. MORITA T, NAGAKI T, FUKUDA I et al. Clastogenicity of low pH to various cultured mammalian cells. Mutat Res 1992;268:297-305.
37. SEMENZA GL, AGANI F, BOOTH G et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 1997;51:553-5.
38. JAAKKOLA P, MOEL DR, TIAN YM et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitilytion complex by O2 regulated prolyly hydoxylation. Science 2001;292:468-72.
39. WYKO CC, PUGH CW, MAXWELL PH et al. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 2000;19:6297-305.
40. CLIORD SC, COCKMAN ME, SMALLWOOD AC et al. Contrasting effects of HIF alpha regulation by disease-causing pVHL mutations correlate with patterns of tumour genesis in von Hippel-Lindau disease. Hum Mol Genet 2001;10:1029-38.
41. JURKOWITZ MS, LITSKY ML, BROWING MJ et al. Adenosine, inosine and guanosien protect glial cells during glucose deprivation and mitochondrial inhibition: correlation between protection and ATP preservation. J Neurochem 1998;71:535-48.
42. TREPSTA M, GRUETTER R, HIGH WB et al. Lactate turnover in rat glioma measured by in vivo nuclear magnetic resonance spectroscopy. Cancer Res 1998;58:5083-88.
43. GILLIES RJ, SCHOMACK PA, SECOMB TW et al. Causes and effects of heterogenous perfusion in tumors. Neoplasia 1999;1:197-207.
44. SONODA Y, KANAMORI M, DEEN DF et al. Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to gliobalsotma multiforme in a human model of gliomagenesis. Cancer Res 2003;63:1962-8.
45. CHENG SY, NAGANE M, HUANG HS et al. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci USA, 1997;28:12081-7.
46. CHENG SY, HUANG HJM NAGANE M et al. Suppression of glioblastoma angiogenicity and tumorgenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1996;93:8502-7.
47. GUO P, XU L, PAN S et al. Vascular endothelial growth factor isoforms displays distinct activities in promoting tumor angiogenesis at different anatomic sites. Cancer Res 2001;61:8569-77.
48. LOBOV KB, BROOKS PC, LANG RA. Angiogenesis-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002;99:11205-10.
49. PEOCH M, FARION R, HION A et al. Immunohistochemical study of VEGF, angiopoietin 2 and their receptors in the neovascularization following microinjection of C6 glioma cells into rat brain. Anticancer Res 2002;22:2147-51.
50. NIDER C, SCHLEGEL J, ANDRATSCHKE N et al. The role of growth factors in central nervous system tumors. Anticancer Res 2003;23:1681-6.
51. GRITHS JR. Causes and consequences of hypoxia and acidity in tumor microenvironments. Bioessays 2001;23:295-6.
52. RACKER E. Why do tumor cells have a high aerobic glycolysis? J Cell Physiol 1976;89:697-700.
53. RACKER E, SPECTOR M. Warburg effect revisited: merger of biochemistry and molecular biology. Science 1981;213:303-7.
54. GILIES RJ, RAGHUNAND N, KARCZMAR GS et al. MRI of the tumor microenvironment. J Magn Reson Imaging 2002;16:430-50.
55. RODRIGUEZ-ENRIQUEZ S, MORENO-SANCHEZ R. Intermediary metabolism of fast-growth tumor cells. Arch Med Res 1998;29:1-12.
56. SEAGROVES T, RYAN HE, LU H et al. Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol Cell Biol 2001;21:3436-44.
57. ZHONG H, AGANI F, BACCALA AA et al. Increased expression of hypoxia inducible factor 1 alpha in rat and human prostate cancer. Cancer Res 1998;58:5280-4.
58. FLANNERY T, GIBSON D, MIRAKHUR M et al. The clinical significance of cathepsin S expression in human astrocytomas. Am J Pathol 2003;163:175-82.
59. REICHLING DB, KYROZIS A, WANG J et al. Mechanisms of GABA and glycine depolarization-induced calcium transient in rat dorsal hom neurons. J Physiol (Lond) 1994;476:411-21.
60. MAGAVI SS, MACKLIS JD. Induction of neuronal type-specific neurogenesis in the cerebral cortex of adult mice: manipulation of neuronal precursors in situ. Brain Res Dev Brain Res 2002;134:57-76.
61. LEE JC, MAYER-PROSCHEL M, RAO MS. Gliogenesis in the central nervous system. Glia 2000;30:105-21.
62. REE AH, BRATLAND A, KROES RA et al. Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases. Anticancer Res 2002;22:1949-57.
63. WANG J, KLEM J, WYRICK JB et al. Detection of hypoxia in human brain tumor xenografts using a modified comet assay. Neoplasia 2003;5:288-96.
64. KRAFT R, BASRAI D, BENNDORF C et al. Serum deprivation and NGF induce and modulate voltage-gated Na(+) currents in human astrocytes cell lines. Glia 2001;34:59-67.
65. HURTBLUT WP, CHIEREGATTI E, VALTORTU F et al. Alpha-lactotoxin channels in neuroblastoma cells. J Membr Biol 1994;138:91-102.
66. JUSSOFIE A, REINHARD V, KAL R. GABA binding sites: their density, their affinity to muscimol and their behaviour against neuroactive steroids in human gliomas of different degrees of malignancy. J Neural Transm 1994;96:233-41.
67. LABRAKAKIS C, PATT S, HARTMANN J et al. Functional GABA(A) receptors on human glioma cells. Eur J Neurosci 1998;10:231-8.
68. LABRAKAKIS C, PATT S, HARTMANN J et al. Glutamate receptor activation can trigger electrical activity in human glioma cells. Eur J Neurosci 1998;10:2153-62.
69. BROWN RC, DEGENHARDT B, KOTOULA M et al. Location-dependent role of the human glioma cell peripheral-type benzodiazepine receptors in proliferation and steroid biosynthesis. Cancer Lett 2000;156:125-32.
70. - conductance increase and a K+ channel blockade in cerebellar granule cells. Neuroscience 1997;79:177-89.
71. LABRAKAKIS C, PATT S, WEYDT P et al. Action potential generating cells in human glioblastoma. J Neuropathol Exp Neurol 1997;56:243-54.
72. BORDEY A, SOUTHEIMER H. Electrophysiological properties of human astrocytic tumor cell in situ: enigma of spiking glial cells. J Neurophysiol 1998;79:2782-93.
73. LIN J, MORROW AL, DEVAUD L. GABA A receptors mediate trophic effects of GABA on embryonic brainstem monoamine neurons in vitro. J Neurosci 1997;17:2420-8.
74. ANTONOPOULOS J, PAPPAS IS, PAMAVELAS JG. Activation of the GABA A receptor inhibits the proliferative effects of bFGF in cortical progenitor cells. Eur J Neurosci 1997;9:291-8.
75. GANSDOLFO P, PATTE C, THOUMAS JL et al. The endozepne ODN stimulates (3H) thymidine incorporation in cultured rat astrocytes. Neuropharmacology 1999;38:725-32.
76. MIETTINEN H, KONONEN J, HAAPASALO H et al. Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas. Relationship to cell proliferation. Cancer Res 1995;55:2691-5.
77. TIAN J, CHAU C, HALES TG et al. GABA(A) receptors mediate inhibition of T cell responses. J Neuroimmunol 1999;96:21-8.
78. 18F)-fluorodeoxyglucose and positron emission tomography before and after surgical resection of epileptogenic cavernous angiomas. Stereotact Funct Neurosurg 1997;69:225-8.
79. CASAZZA M, BROGGI G, FRANZINI A et al. Supratentorial cavernous angiomas and epileptic seizures: preoperative course and postoperative outcome. Neurosurgery 1996;39:26-32.
80. RASSI NETO A, RIBEIRO PR, PRATES MA et al. Surgical treatment of cerebral vascular pathologies in epileptic patients. Arq Neuropsiquiatr 1997;55:408-12.
81. AWAD IA, ROSENFELD J, AHL J et al. Intractable epilepsy and structural lesions of the brain: mapping resection strategies, and siezure outcome. Epilepsia 1991;32:179-86.
82. HIRSCH JF, SAINTE-ROSE C, PIERRE-KAHN A et al. Benign astrocytic and oligodendrocytic tumors of the cerebral hemispheres in children. J Neurosurg 1989;70:568-72.
83. ACKERMANN RF, FINCH DM, BABB TL et al. Increased glucose metabolism during long-duration recurrent inhibition of hippocampal pyramidal cells. J Neurosci 1984;4:251-64.
84. 14C)2-deoxyglucose labeling of synaptic activity in the central auditory system. J Comp Neurol 1986;245:553-65.
85. ROTHMAN DL, SIBSON NR, HYDER F et al. In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics. Philos Trans R Soc Lond B 1999;354:1165-77.
86. ZAGZAG D, FRIEDLANDER DR, MARGOIS B et al. Molecular events implicated in brain tumor angiogenesis and invasion. Pediatr Neurosurg 2000;33:49-55.
87. ZENTER J, HUFNAGEL A, WOLF HK et al. Surgical treatment of neoplasms associated with medically intractable epilepsy. Neurosurgery 1997;41:378-87.
88. BHUJWALLA Z, SHUNGU D, GLCISON J. Susceptibility maps of tumors and their relationship to histopathological characteristics and flow. In: Book of abstracts: Annual scientific meeting and exhibition. New York: Society for Magnetic Resonance in Medicine, 1993;142.